Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

What Was Tested

The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

To evaluate elimination and degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney failure.

Why It Was Studied

The affect of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear.

Who Took Part

The study group was 12 subjects.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Twelve non-diabetic patients treated with chronic hemodialysis and 12 control subjects were examined in a double-blind, randomized, matched observational study at the Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

Blinding on both sides kept the subjects and researchers unaware of who received GIP (Gastric Inhibitory Polypeptide).

Some subjects received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.

Over 4 separate study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of dipeptidyl peptidase 4 using sitagliptin or placebo.

Plasma concentrations of glucose, insulin, glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly.

Plasma half-life (T1/2), metabolic clearance rate (MCR), area under curve, and volume of distribution for intact and metabolite levels of GLP-1 and GIP were calculated.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Denmark, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Fasting, Gastric Inhibitory Polypeptide and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 12 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.